Curis, Inc. (CRIS) News

Curis, Inc. (CRIS)

Today's Latest Price: $1.44 USD

0.07 (5.11%)

Updated Nov 27 1:00pm

Add CRIS to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 389 in Biotech

See all "A" rated Strong Buy stocks

Filter CRIS News Items

CRIS News Results

Event/Time Symbol Company News Detail Start End Change POWR Rating
Loading, please wait...

Latest CRIS News From Around the Web

Below are the latest news stories about Curis Inc that investors may wish to consider to help them evaluate CRIS as an investment opportunity.

Curis to Present at Upcoming Investor Conferences

LEXINGTON, Mass. , Sept. 10, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS ), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer , President and Chief Executive Officer of Curis, will provide a company overview at two upcoming investor conferences: … Full story available on Benzinga.com

Benzinga | September 10, 2020

Curis, Inc. (CRIS) CEO Jim Dentzer on Q2 2020 Results - Earnings Call Transcript

Curis, Inc. (CRIS) Q2 2020 Earnings Conference Call August 04, 2020 04:30 PM ET Company Participants Bill Steinkrauss - Chief Financial Officer Jim Dentzer - President & Chief Executive Officer Bob Martell - Head of R&D Conference Call Participants Alethia Young - Cantor Soumit Roy - JonesTrading Yale Jen -...

SA Transcripts on Seeking Alpha | August 5, 2020

Curis Doses First Patient in Phase 1 Study of CA-4948 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the first patient has been dosed in its Phase 1 trial evaluating CA-4948, a novel, small molecule IRAK4 kinase inhibitor, in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS) with spliceosome mutations, such as SF3B1 and U2AF1, that drive expression of the long isoform of IRAK4 (IRAK4-L). IRAK4 plays an essential role in the toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling pathways, and these pathways are frequently dysregulated in patients with AML and MDS.

Yahoo | July 7, 2020

Edited Transcript of CRIS earnings conference call or presentation 12-May-20 8:30pm GMT

Q1 2020 Curis Inc Earnings Call

Yahoo | June 22, 2020

The Only Way To Play Curis

Source: Company website Companies like Curis (CRIS) attract speculators, traders and pumpers because of the relatively easy way the stock price can be temporarily manipulated to give it a big boost, or in some cases, respond to press releases issued to generate a quick boost in the share price. Many...

Gary Bourgeault | June 12, 2020

Curis plunges 18% on launch of direct offering

Curis ([[CRIS]] -18.2%) inks agreement for the purchase and sale of 14M common shares at a purchase price of $1.25/share in a registered direct offering, for expected gross proceeds of $17.5M. Net proceeds will be used to continue development of CA-4948 and CI-8893, and for general working capital and capital...

Seeking Alpha | June 11, 2020

Curis Announces $17.5 Million Registered Direct Offering

LEXINGTON, Mass., June 11, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it has entered into definitive agreements with fundamental healthcare investors for…

PR Newswire | June 11, 2020

Curis poised to add to rally

Thinly traded nano cap Curis (CRIS) is up 74% premarket on robust volume, poised to add to yesterday's 42% gallop.No particular news accounts for the action, but a capital raise will be needed this year.At the end of March, it had $12.5M in cash and equivalents while operations consumed $9.0M in Q1. Its earnings...

Seeking Alpha | June 10, 2020

Healthcare - Top 5 Gainers / Losers

Gainers: Curis (CRIS) +111%. Celldex Therapeutics (CLDX) +27%. T2 Biosystems (TTOO) +16%. Teligent (TLGT) +14%. CNS Pharmaceuticals (CNSP) +11%.Losers: Immuron (IMRN) -41%. Second Sight Medical Products (EYES) -20%. Can-Fite BioPharma (CANF) -19%. Capital Senior Living (CSU) -17%. GNC Holdings (GNC) -15%....

Seeking Alpha | June 10, 2020

The 'Important Step' For Nano-Cap Biopharma Curis That's Sending Shares Higher

Shares of nano-cap biopharma Curis, Inc. (NASDAQ: CRIS ) are on a strong two-day run that has lifted the equity from penny stock territory. What Happened: The Lexington, Massachusetts-based company, which focuses on developing innovative therapies for treating cancer, said the FDA has cleared its investigational new drug application for its CI-8993 asset. CI-8993 is a monoclonal anti-VISTA antibody. It acts by blocking VISTA, which plays a key role in suppressing T-cell activity when activated. Blocking VISTA reduces the suppression of T-cells and anti-tumor … Full story available on Benzinga.com

Benzinga | June 10, 2020



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.527 seconds.